BA

Baxter International Inc.

BAXHealthcareNASDAQ

Medical Instruments & Supplies

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$11.24B
+5.7% YoY
Net Income
-$957.0M
-47.5% YoY
EBITDA
$766.0M
-31.4% YoY
Free Cash Flow
$1.00B

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 19 MACD Negative CrossoverHistogram -0.2617, negative momentum
Aug 18 MACD Negative CrossoverHistogram -0.1883, negative momentum
About Baxter International Inc.

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. With a market capitalization of $13.35B, it sits in large-cap territory. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.

Where BAX stands vs its 150-day and 200-day moving averages

As of the August 19, 2026 close, BAX finished 28.67% above its 150-day moving average ($20.16) and 30.88% above its 200-day moving average ($19.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is BAX overbought or oversold?

At the August 19, 2026 close, BAX's RSI(14) was 56.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$13.35B
Fwd P/E12.68
EPS$-1.88
Beta0.59
52W Change+5.6%
Dividend Yield0.15%
ROE-14.4%
Analysis

Baxter International Inc. carries $9.67B in total debt against $2.15B in cash reserves — debt is roughly 4.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $1.00B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -14.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.9% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $10.06B to $11.24B.

The relatively low beta of 0.59 suggests BAX is a less volatile holding compared to the broader index. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Baxter International Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms